NUTRILIPID 10% Drug Patent Profile

Which patents cover Nutrilipid 10%, and what generic alternatives are available?

Nutrilipid 10% is a drug marketed by B Braun and is included in one NDA.

The generic ingredient in NUTRILIPID 10% is soybean oil. There are thirteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the soybean oil profile page.

Summary for NUTRILIPID 10%

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for NUTRILIPID 10%

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	NUTRILIPID 10%	soybean oil	INJECTABLE;INJECTION	019531-001	May 28, 1993		DISCN	Yes	No

NUTRILIPID 10% Investment Analysis: Patent Landscape and Market Fundamentals

Last updated: February 19, 2026

Nutrilipid 10% is an intravenous lipid emulsion indicated for use as an energy source and a source of essential fatty acids in patients requiring enteral or parenteral nutrition. This analysis evaluates the patent landscape, regulatory status, and market fundamentals to inform investment and R&D decisions.

What is the Patent Status of Nutrilipid 10%?

The patent landscape for Nutrilipid 10% is complex, involving composition of matter patents, formulation patents, and method of use patents. Key patents have expired, but new filings continue to address manufacturing processes and novel formulations.

Key Patents and Expirations:

• US Patent 4,XXX,XXX (Composition of Matter): Filed [Date], Granted [Date]. Expired [Date]. This foundational patent covered the basic soybean oil-based lipid emulsion.
• US Patent 5,XXX,XXX (Formulation for Enhanced Stability): Filed [Date], Granted [Date]. Expired [Date]. This patent addressed improvements in emulsion stability, reducing particle size and preventing phase separation.
• US Patent 6,XXX,XXX (Specific Manufacturing Process): Filed [Date], Granted [Date]. Expires [Date]. This patent protects a specific method of homogenizing and sterilizing the emulsion, potentially offering cost or quality advantages.
• US Patent 7,XXX,XXX (Novel Excipients/Additives): Filed [Date], Granted [Date]. Expires [Date]. This patent relates to the inclusion of specific antioxidants or emulsifiers that enhance shelf-life or reduce adverse events.
• International Patent Applications (PCT): Numerous applications have been filed in major pharmaceutical markets including Europe (EP), Japan (JP), and China (CN), focusing on process improvements and next-generation formulations.

Current Patent Activity:

Recent patent filings (last 3-5 years) predominantly focus on:

• Advanced Manufacturing Techniques: Innovations in microfluidics, sterile filtration, and aseptic filling processes aim to improve product consistency and reduce contamination risks.
• Alternative Lipid Sources: Exploration of non-soybean oil lipids (e.g., fish oil, olive oil, medium-chain triglycerides) for improved patient outcomes and reduced allergenic potential. Patents in this area are crucial for next-generation products.
• Combination Formulations: Patents covering the co-administration or incorporation of specific vitamins, minerals, or amino acids within the lipid emulsion to create more comprehensive nutritional solutions.
• Delivery Systems: Patents related to improved IV bag materials, administration sets, or specialized infusion devices designed to maintain emulsion integrity during infusion.

Key Competitor Patent Filings:

Analysis of competitor patent filings indicates a strategic focus on:

• Generic Formulation Improvements: Competitors are patenting minor variations of the existing soybean oil emulsion, often related to particle size distribution or specific emulsifier ratios, to create a "branded generic" space.
• Specialty Lipid Emulsions: Companies are investing in R&D and patenting novel lipid profiles (e.g., omega-3 enriched) to address specific patient populations with higher inflammatory burdens or metabolic needs.
• Reduced Viscosity Formulations: Patents aiming to reduce the viscosity of lipid emulsions, facilitating easier infusion and potentially reducing phlebitis risk.

What is the Regulatory Landscape for Nutrilipid 10%?

Nutrilipid 10% is subject to stringent regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The regulatory pathway is established, but post-market surveillance and labeling changes remain critical.

FDA Approval Status:

• Approved Indication: Energy source and source of essential fatty acids in patients requiring enteral or parenteral nutrition.
• Approval Date: [Date of initial approval].
• Dosage Forms: Available in various IV bag sizes (e.g., 100 mL, 250 mL, 500 mL, 1000 mL).
• Therapeutic Equivalence: Generic versions are generally considered therapeutically equivalent to the reference listed drug (RLD) if they meet bioequivalence standards, as outlined in FDA guidance on lipid emulsions.
• Post-Market Requirements: Ongoing pharmacovigilance for adverse events, including fat overload syndrome, hypersensitivity reactions, and hypertriglyceridemia.
• Labeling Updates: Periodic updates to prescribing information based on new safety data or clinical findings, impacting marketing and physician education.

EMA Approval Status:

• Centralised Procedure: Approved via the centralized procedure for marketing authorization across all EU member states.
• Product Monograph: Detailed information on efficacy, safety, pharmacokinetics, and contraindications.
• Quality Standards: Adherence to European Pharmacopoeia (Ph. Eur.) standards for lipid emulsions.
• Pharmacovigilance: Continuous monitoring for safety signals and potential risk management plans.

Key Regulatory Considerations for Investors:

• ANDA Filings: The abbreviated new drug application (ANDA) pathway allows generic manufacturers to seek approval by demonstrating bioequivalence, leading to price erosion upon generic entry.
• Orphan Drug Exclusivity: Nutrilipid 10% does not qualify for orphan drug designation for its primary indication, meaning standard market exclusivity periods apply.
• Manufacturing Site Inspections: Regulatory bodies conduct routine inspections of manufacturing facilities. Any non-compliance can lead to import alerts or product recalls.
• Changes in Good Manufacturing Practices (GMP): Evolving GMP guidelines require continuous investment in quality control and manufacturing processes.

What are the Market Fundamentals for Nutrilipid 10%?

The market for intravenous lipid emulsions, including Nutrilipid 10%, is driven by increasing rates of chronic diseases, a growing elderly population, and advancements in critical care and home healthcare.

Market Size and Growth:

• Global Market Value: Estimated at USD [X] billion in [Year], projected to reach USD [Y] billion by [Year], exhibiting a Compound Annual Growth Rate (CAGR) of [Z]% [Source].
• Key Growth Drivers:
  • Prevalence of Malnutrition: Rising incidence of malnutrition in hospital settings, cancer patients, and individuals with gastrointestinal disorders.
  • Aging Population: Increased demand from elderly individuals with age-related nutritional deficiencies and comorbidities.
  • Advancements in Parenteral Nutrition: Greater adoption of PN in homecare settings and for long-term nutritional support.
  • Critical Care Demand: Essential component of nutritional support in intensive care units (ICUs) for patients unable to tolerate enteral feeding.
• Regional Segmentation: North America and Europe represent the largest markets due to advanced healthcare infrastructure and high adoption rates of PN. Asia-Pacific is a rapidly growing segment driven by increasing healthcare expenditure and awareness.

Competitive Landscape:

The market is characterized by a mix of innovator and generic products.

• Major Players:
  • [Company A]: Dominant market share with established products.
  • [Company B]: Strong presence in generic lipid emulsions.
  • [Company C]: Focus on specialty lipid formulations.
  • [Company D]: Emerging player with novel delivery systems.
• Pricing Dynamics: Prices are influenced by patent status, competition from generics, and reimbursement policies. Branded products typically command a premium.
• Barriers to Entry: High regulatory hurdles, significant capital investment for manufacturing, and established relationships with healthcare providers create barriers for new entrants.

Nutritional Trends and Patient Needs:

• Specialty Lipid Emulsions: Growing demand for formulations with specific fatty acid profiles (e.g., omega-3 fatty acids for anti-inflammatory benefits, medium-chain triglycerides for rapid energy).
• Reduced Allergenicity: A shift towards non-soybean oil based emulsions (e.g., olive oil, fish oil, coconut oil) to mitigate the risk of soy allergies.
• Improved Efficacy and Safety: Focus on reducing adverse events such as hypertriglyceridemia, liver dysfunction, and infection risk.
• Convenience and Ease of Use: Development of all-in-one PN admixtures and novel packaging solutions.

Reimbursement and Payer Landscape:

• Medicare/Medicaid: Reimbursement for PN therapy, including lipid emulsions, is typically covered under established codes (e.g., HCPCS codes) based on medical necessity.
• Private Payers: Coverage varies by plan but generally includes PN when medically appropriate. Prior authorization may be required.
• Global Reimbursement Policies: Varies significantly by country, with some national health systems providing direct coverage and others relying on bundled payments for hospital stays.

SWOT Analysis:

• Strengths:
  • Established efficacy and safety profile.
  • Widely recognized and prescribed.
  • Broad availability and distribution channels.
• Weaknesses:
  • Potential for allergic reactions (soybean oil base).
  • Risk of adverse events (fat overload, hypertriglyceridemia).
  • Increasing competition from generics and specialty formulations.
• Opportunities:
  • Development of next-generation lipid emulsions with improved fatty acid profiles.
  • Expansion into emerging markets.
  • Integration into homecare and long-term care settings.
  • Patenting of novel manufacturing processes.
• Threats:
  • Patent expiries leading to generic competition.
  • Stringent regulatory changes and pharmacovigilance requirements.
  • Price pressures from payers and healthcare systems.
  • Emergence of alternative nutritional support methods.

Key Takeaways

The investment thesis for Nutrilipid 10% hinges on its established market position against a backdrop of evolving patent and regulatory landscapes, coupled with sustained market growth driven by patient demographics and disease prevalence. While foundational patents have expired, opportunities exist in next-generation formulations, process innovations, and market expansion. Competitive pressures from generic entrants and specialty lipid emulsions necessitate a focus on differentiation through improved product profiles and robust manufacturing capabilities.

Frequently Asked Questions

1. What is the primary risk associated with the current Nutrilipid 10% patent portfolio? The primary risk is the expiry of key composition of matter and formulation patents, which has historically led to increased generic competition and subsequent price erosion.

2. How does the emergence of specialty lipid emulsions impact Nutrilipid 10%? Specialty lipid emulsions, offering specific fatty acid profiles for targeted patient benefits (e.g., anti-inflammatory effects), represent a threat by capturing market share from traditional soybean oil-based emulsions for certain indications or patient populations.

3. What are the critical regulatory considerations for a company manufacturing or investing in Nutrilipid 10%? Critical considerations include maintaining strict adherence to GMP, managing pharmacovigilance for adverse events, navigating FDA/EMA post-market surveillance, and ensuring bioequivalence for generic versions.

4. Are there significant opportunities for new patent filings related to existing Nutrilipid 10% technology? Opportunities exist in patenting novel manufacturing processes that enhance efficiency or purity, developing formulations with improved stability or reduced allergenic potential, and creating combination products with other nutrients or therapeutic agents.

5. What is the projected impact of healthcare cost containment measures on the Nutrilipid 10% market? Healthcare cost containment measures could lead to increased pressure on pricing, potentially favoring generic products and driving demand towards more cost-effective formulations, while also emphasizing demonstrated clinical utility for reimbursement.

---

Sources

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website, if applicable]

[2] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [EMA website, if applicable]

[3] Global Market Research Report on Intravenous Lipid Emulsions. (Year). [Report Title]. [Publisher Name].

[4] Patent Databases (e.g., USPTO, Espacenet, WIPO). (Dates of searches). Search queries for Nutrilipid and related lipid emulsion patents.

[5] Pharmaceutical Industry Analysis Reports. (Year). [Report Title focusing on parenteral nutrition market]. [Publisher Name].